Effective Ancillary Fees for Raising Capital

September 13, 2022

When it comes to raising capital, there are many associated costs. From legal and accounting fees to marketing and advertising expenses, costs can quickly add up. So how can issuers recoup some of these costs? One way is by setting up ancillary fees on your offering. Ancillary fees are voluntary charges in addition to the security price. Predominantly, these fees have been used to offset some of the expenses associated with raising capital. However, our data shows that using ancillary fees can actually drive higher investments when used strategically. But what exactly are ancillary fees, and how do they work? Let's take a closer look

What are Ancillary Fees?

Ancillary fees can cover the costs of listing the security on a stock exchange or other market platform. For an ancillary fee to be assessed, the capital raising event must involve the sale of equity securities. The ancillary fee is then charged as a percentage of the aggregate gross proceeds from selling those securities. Issuers must also disclose how the proceeds from the fee will be used. Ancillary fees are not typically assessed on every transaction but rather on a per-security basis. 

How Do Ancillary Fees Work?

Ancillary fees are generally assessed when the security is first issued or sold in the secondary market. There are many ways to structure ancillary fees to recoup your costs- outlined below are three of the most common.

Option 1: FLAT FEE

Charge a flat ancillary fee across the board applicable to all investors. A commonly used formula to calculate an ancillary fee is (Minimum Investment Amount x 1.5) x 2%. This means a raise with a $1000 minimum investment and a $30 ancillary fee would be charged at any amount invested.

Option 2: FEE AS A PERCENTAGE

You have the option to charge an ancillary fee as a set % of the amount invested. For example, an issuer may choose to implement a 1.5% ancillary fee - an investor purchasing $1000 of securities would pay a $15 ancillary fee, while an investor purchasing $6000 would pay a $90 ancillary fee.

Option 3: TIERED STRATEGY

A tiered ancillary fee often finds a flat ancillary fee charged up to a certain threshold, after which it is completely waived. For example, an issuer with a $1000 minimum investment amount may charge a $30 fee but offer to waive it for investors who invest more than $2500. *Hint: We've seen this strategy drive higher investments in our data!

Used wrong, fees can prevent a sale. Used right, fees can increase a sale

One crucial factor to consider when implementing ancillary fees is the minimum investment amount. For raises with lower minimum investment amounts, charging investors an ancillary fee may dissuade investors and negatively impact your conversion rates. In these circumstances, the fee will make the investment less attractive than other options on the market, leading potential investors to look elsewhere. In this case, instead of recouping costs the ancillary fee interrupted (and prevented) the sale - ultimately negatively impacting the overall raise. 

Understanding how to strategically use fees to yield the best results is crucial if you choose to leverage an ancillary fee structure. At DealMaker, we have found an interesting trend in investor behavior when the ancillary fee is waived at a certain threshold. This is likely due to the investor's perceived additional fee cost versus the much higher investment value to get no fee. Essentially, strategically waiving the fee can increase your average investment amounts per investor.

Before implementing any ancillary fees, consult with your broker-dealer and lawyers to ensure all SEC filing requirements are completed, and your due diligence is met.

Conclusion

Ancillary fees are a tool that issuers can use to offset some of the expenses associated with raising capital. By taking the time to analyze if implementing an ancillary fee on your raise makes financial sense, you can find the opportunity to build an effective strategy which (our data shows) can also boost the performance of your capital raise overall. 

Monogram Case Study - DealMaker (Embed)

When VCs said no, Monogram turned to retail investors. That decision powered their rise from startup to publicly traded company—and even helped them raise an additional $13M privately after their Nasdaq debut.

Monogram at NASDAQ celebration

The Challenge: Raising Capital on Their Terms

The Challenge: Raising on Their Terms

Monogram Technologies was founded with a bold vision: to revolutionize orthopedic surgery with a robotic joint replacement system using custom 3D-printed joints. The market for this technology is massive—approximately $19.6 billion, with over 1 million knee replacements per year. But it's a capital-intensive, regulation-heavy space—and traditional VCs weren't biting.

Instead of compromising, co-founders Dr. Doug Unis and Ben Sexson went all-in on a different path: retail capital. Why?

  • Control and ownership: Not only were they able to raise the capital they needed to grow the business—they did it on their own terms.
  • Long-term asset: They wanted to build an army of true believers who wanted to see the company succeed and would continue to reinvest over the years.
  • A value-add network: Raising from retail allowed Monogram to amass a waiting list of thousands of patients eager to participate in future trials.
  • Aligned incentives: Their mission to improve patient outcomes and build a better future for those struggling with joint pain resonated with retail investors.

The Power of Retail: Monogram's Capital Journey

Start Date End Date Type Platform Amount Raised # Investors
3/13/193/31/20A+SeedInvest$14,588,6686,000
11/16/201/16/21A+StartEngine$2,965,5018,000
1/17/212/18/22A+StartEngine$23,647,85314,082
7/15/223/16/23CFDealMaker$4,673,0002,249
3/1/234/8/23A+Republic$232,275120
3/1/235/23/23A+DealMaker$15,958,3645,198
5/18/23-Nasdaq listing
7/2410/24Unit OfferingDealMaker$12,990,1032,745

Monogram Capital Raise Timeline

Monogram's first direct-to-investor raise was a $14.6M round in 2019. Since then, Monogram has raised retail capital six additional times, using Reg A+ as a springboard to a Nasdaq listing in 2023.

Each raise brought in new believers—and more importantly, kept bringing them back. That's the long-term power of retail capital. It's not just one campaign—it's a compounding asset that grows with the business.

$80M+
Raised across seven campaigns
~40,000
Investors championing Monogram's vision
20%
Of each raise came from previous investors

Marketing Excellence

DealMaker Reach provided strategic investor acquisition services, helping Monogram connect with the right audience through high-impact channels.

Premium Publications

Targeted campaigns in premium publications like Morning Brew captured qualified investors

High-Engagement Webinars

Engaging events that generated over $4.3 million in investments

Community Building

Strategic approaches that fostered a loyal shareholder base

Investment Momentum

Innovative approaches that amplified investment momentum

Monogram's Journey to Success

Monogram's journey has been defined by relentless innovation, strategic fundraising, and breakthrough advancements in robotic-assisted joint replacement. From early-stage research to a Nasdaq listing and beyond, Monogram's milestones reflect its evolution into a pioneering force in orthopedic surgery:

  • Filed its first patent application in 2017
  • Conducted clinical studies at UCLA and University of Nebraska
  • Expanded the team with key hires
  • Attracted a top-tier advisory board to guide clinical innovations
  • Signed their first distribution partnerships
  • Made headlines with cutting-edge live demonstrations
  • Secured 501(k) FDA clearance for the mBôs surgical system

Nasdaq Debut & Beyond

In May 2023, Monogram Orthopaedics successfully listed on the Nasdaq—a significant milestone offering liquidity and growth opportunities for the company.

For most companies, that would be the end of their story in the private markets. But for Monogram, it was just the beginning of a new chapter.

Public perception says you can't raise privately post-IPO. Monogram proved that wrong.

Defying conventional fundraising norms, Monogram raised an additional $13 million from private investors, powered by DealMaker. This move highlighted the power of a dedicated investor community and provided additional strategic growth capital. Meanwhile, strategic digital marketing for the private offering helped boost the public share price—a win-win for the company and its investors, both public and private.

This was retail capital at its best: strategic, repeatable, and aligned.

One vision. Zero compromises.

This wasn't a one-time raise. It was a multi-year capital strategy.

Retail capital helped Monogram:

  • Go from concept to commercialization without relying on VCs
  • Retain ownership and control in a high-burn industry
  • Build a base of loyal shareholders who invested not once, but over and over again
  • Uplist to the Nasdaq, and still keep raising post-IPO

This is what makes retail capital different. It doesn't expire—it compounds. And DealMaker is built to maximize that long-term value.

Dr. Doug Unis Quote
Ben Sexson Quote

Ready to Raise Capital on Your Terms?

Whether you're pre-revenue or post-IPO, DealMaker gives you the infrastructure, support, and strategy to raise from the people who believe in you most.

Explore Raising Capital with DealMaker
DealMaker Logo

The ultimate technology for raising capital online

Talk to the experts
The ultimate technology for raising capital online - talk to the experts